Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006

Published: 2009-06-08

Articles

Nuclear medicine perspective on radioimmunotherap

S Fanti, G Montini, M Farsad

https://doi.org/10.4081/hmr.v2i7.395

132

PDF: 244
- PDF
Target long-term responders in indolent non-Hodgkin’s lymphoma: 90Y-ibritumomabtiuxetan

C Emmanouilides

https://doi.org/10.4081/hmr.v2i7.396

190

PDF: 215
- PDF
Impact of radioimmumotherapy on aggressive non-Hodgkin’s lymphoma

PL Zinzani

https://doi.org/10.4081/hmr.v2i7.397

139

PDF: 110
- PDF
Novel pathogenetic mechanisms and therapeutic targets in B cell lymphomas

R Dalla-Favera

https://doi.org/10.4081/hmr.v2i7.398

113

PDF: 140
- PDF
Hodgkin’s lymphoma and Grey-zone lymphomas

F Facchetti, M Ungari, A Ubiali

https://doi.org/10.4081/hmr.v2i7.399

171

PDF: 1586
- PDF
Incorporation of PET scanning into contemporary management programs for Hodgkin’s disease

RT Hoppe

https://doi.org/10.4081/hmr.v2i7.400

116

Untitled (): 0

PDF: 165
- PDF
Current directions in the treatment of early stage Hodgkin’s lymphoma

DJ Straus

https://doi.org/10.4081/hmr.v2i7.401

145

PDF: 349
- PDF
Combined modality treatment for early-stage Hodgkin’s lymphoma: the GHSG experience

S Sasse, V Diehl, A Engert

https://doi.org/10.4081/hmr.v2i7.402

150

PDF: 1003
- PDF
Management of advanced Hodgkin’s lymphoma

GP Canellos

https://doi.org/10.4081/hmr.v2i7.403

136

PDF: 422
- PDF
Dissecting the natural history of chronic lymphocytic leukemia to discover new therapeutic targets

F Caligaris-Cappio, C Scielzo, M Muzio, RM Carletti, A Camporeale, M Frenquelli, C Fazi, M Alessio, A Bachi, P Ghia

https://doi.org/10.4081/hmr.v2i7.404

191

PDF: 205
- PDF
Monoclonal antibodies in the treatment of chronic lymphocytic leukemia

MJ Keating

https://doi.org/10.4081/hmr.v2i7.405

178

PDF: 168
- PDF
New approaches to front-line therapy in multiple myeloma patients aged over 60 years

JF San-Miguel, MV Mateos

https://doi.org/10.4081/hmr.v2i7.406

147

PDF: 165

Untitled (): 0
- PDF
Are there differences in the treatment strategies and outcomes between high-risk multiple myeloma patients and those with low-risk disease and without comorbities?

J Drach

https://doi.org/10.4081/hmr.v2i7.407

141

PDF: 197
- PDF
Practical issues involved with the use of bortezomib

S Lonial

https://doi.org/10.4081/hmr.v2i7.408

122

PDF: 137
- PDF
Improving the treatment paradigm for non-Hodgkin’s lymphoma with bortezomib

PL Zinzani

https://doi.org/10.4081/hmr.v2i7.409

152

PDF: 107
- PDF
The prognosis of follicular lymphomas: the F2-project

M Federico, M Bellei

https://doi.org/10.4081/hmr.v2i7.410

154

PDF: 230
- PDF
The evolution of follicular and the relevance of transformation to DLBCL

A Lister

https://doi.org/10.4081/hmr.v2i7.411

115

PDF: 94
- PDF
Reduced intensity allogeneic transplant for low grade non Hodgkin’s lymphoma

AH Goldstone

https://doi.org/10.4081/hmr.v2i7.412

137

PDF: 113
- PDF
Development of a predictive model for tumour lysis syndrome in patients with acute myeloid leukemia

P Montesinos

https://doi.org/10.4081/hmr.v2i7.413

177

PDF: 294
- PDF
Palonosetron, second generation 5-HT3 antagonist: a new perspective in CINV management

PP Piccaluga

https://doi.org/10.4081/hmr.v2i7.414

161

PDF: 155
- PDF
Azacytidine: first therapeutic opportunity for myelodysplastic syndromes

C Finelli, C Bosi, G Martinelli, M Baccarani

https://doi.org/10.4081/hmr.v2i7.415

190

PDF: 299
- PDF
Posaconazole: a new option for invasive fungal infection management

A Nosari

https://doi.org/10.4081/hmr.v2i7.416

193

PDF: 582
- PDF
PLiposomal doxorubicin: emergent data in lymphoproliferative disease

L Rigacci

https://doi.org/10.4081/hmr.v2i7.417

130

PDF: 256
- PDF
Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals two distinct subgroups and recurrent pdgfr-alpha deregulation

SA Pileri, PP Piccaluga, C Agostinelli, S Zupo, F Facchetti

https://doi.org/10.4081/hmr.v2i7.418

158

PDF: 179
- PDF
Molecular pathogenesis of diffuse large B-cell lymphoma

G Saglio, M Bosa, M Gino, S Ulisciani, G Parvis

https://doi.org/10.4081/hmr.v2i7.419

163

PDF: 983
- PDF
Progress in the treatment of diffuse large B-cell lymphomas: a German perspective

M Pfreundschuh

https://doi.org/10.4081/hmr.v2i7.420

141

PDF: 225
- PDF
What will be the future after R-CHOP in patient with DLBCL?

B Coiffier

https://doi.org/10.4081/hmr.v2i7.421

126

PDF: 207
- PDF
High-dose therapy. Experience of the non-Hodgkin’s lymphoma Co-operative Study Group (NHLCSG)

G Santini

https://doi.org/10.4081/hmr.v2i7.422

117

PDF: 107
- PDF
Reduced-intensity allogeneic stem cell transplantation is an effective salvage treatment for relapsed aggressive non-Hodgkin’s lymphoma

P Corradini, A Dodero, M Bregni, A Olivieri, P Valagussa, L Farina

https://doi.org/10.4081/hmr.v2i7.423

138

PDF: 122
- PDF
How important is to eradicate minimal residual disease in indolent non-Hodgkin’s lymphoma?

A Rambaldi

https://doi.org/10.4081/hmr.v2i7.424

160

PDF: 343
- PDF
Follicular lymphoma: maintenance strategies in the spotlight

MHJ van Oers

https://doi.org/10.4081/hmr.v2i7.425

144

PDF: 137
- PDF
The effect of adding rituximab to high dose chemotherapy

U Vitolo, A Chiappella, G Rossi, E Angelucci, M Liberati, E Liberati

https://doi.org/10.4081/hmr.v2i7.426

196

PDF: 380
- PDF
High-dose sequential chemotherapy versus a less intensive regimen followed by peripheral blood autologous hematopoietic stem cell transplantation as salvage treatment in relapsed and refractory Hodgkin’s disease

JT Souto Filho, AC Vigorito, KP Urago, SF Matte, EA Miranda, M Delamain, I Lorand-Metze, CM Duarte

https://doi.org/10.4081/hmr.v2i7.427

170

PDF: 222
- PDF
Allogeneic transplantation for multiple myeloma

I Majolino, E Carnevall, A Locasciulli, P Di Bartolomeo, R Scimè, P Corradini, C Selleri, F Selleri

https://doi.org/10.4081/hmr.v2i7.428

164

PDF: 177
- PDF
Risk assessment for multiple myeloma: the role of bone marrow transplantation

A Maiolino

https://doi.org/10.4081/hmr.v2i7.429

160

PDF: 347
- PDF
Tandem transplant in oncohematology

AM Carella

https://doi.org/10.4081/hmr.v2i7.430

129

PDF: 145
- PDF
Transplantation for low-grade lymphoma

JG Gribben

https://doi.org/10.4081/hmr.v2i7.431

121

PDF: 124
- PDF
The value of PegFilgastrim for the therapy of acute myeloid leukemia

A Ciolli, F Leoni, A Bosi

https://doi.org/10.4081/hmr.v2i7.432

146

PDF: 1560
- PDF
Palifermin, the first specific drug treatment for oral mucositis in bone marrow transplant

E Gallo

https://doi.org/10.4081/hmr.v2i7.433

144

PDF: 258

Untitled (): 0
- PDF
Interactions between myeloma cells and bone microenvironment

N Giuliani, F Morandi, S Tagliaferri, V Rizzoli

https://doi.org/10.4081/hmr.v2i7.434

175

PDF: 169
- PDF
Unconventional properties of zoledronic acid

M Massaia, F Fiore, B Castella, B Pantaleoni, S Mariani, S Peola, SY Hwang

https://doi.org/10.4081/hmr.v2i7.435

167

PDF: 134
- PDF
The impact of new drugs in the high dose strategy

M Attal

https://doi.org/10.4081/hmr.v2i7.436

143

PDF: 128
- PDF
Emerging role for reduced intensity allotransplant in multiple myeloma

B Bruno, M Boccadoro

https://doi.org/10.4081/hmr.v2i7.437

139

PDF: 165
- PDF
New treatment strategies for elderly myeloma patients

A Palumbo, P Falco, P Musto, G Rossi, N Giuliani, F Morabito, A Falcone

https://doi.org/10.4081/hmr.v2i7.438

125

PDF: 201
- PDF

Proceedings

NEW INSIGHTS IN HEMATOLOGY - Posters

Teodoro Chisesi

https://doi.org/10.4081/hmr.v2i7.439

751

PDF: 227
- PDF

© PAGEPress 2008-2024 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185 • Privacy